Mexico Radiotherapy Market Overview, 2031

Key Insights

• The Mexican radiotherapy market is characterized by significant infrastructure deficits relative to cancer burden, creating substantial growth potential. Mexico has approximately 155 to 160 operational megavoltage machines for a population exceeding 130 million, equating to roughly 1.2 machines per million inhabitants well below international benchmarks of 2-3 machines per million and far from the recommended one machine per 250,000 inhabitants, which would require more than 500 units .
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, with linear accelerators forming the backbone of radiation oncology services. The IMSS the largest social security institution in Latin America operates the largest fleet, having renewed 20 of its 30 accelerators in recent years and projecting the construction of 12 additional radiotherapy centers in states including Chiapas, Chihuahua, and Michoacán .
• Radiotherapy systems and equipment represent the largest offering segment, with the market structurally dependent on imports. The United States is the dominant source country for radiotherapy and X-ray equipment, accounting for approximately 42% of Mexico's total imports valued at US$416 million in 2022, followed by Germany, China, and Malaysia .
• Hospitals and integrated cancer centers are the largest end-user segment. However, radiotherapy infrastructure is highly concentrated, with only 56 hospitals possessing radiation therapy areas, and five states including Tlaxcala and Chiapas lacking any brachytherapy capacity .
• Regulatory oversight operates through a dual-licensing framework requiring both a Nuclear Safety Commission license and a COFEPRIS health license for operation. The Mexican Academy of Medicine has identified infrastructure deficits, workforce shortages, and regulatory coordination challenges as the three primary barriers to expanding radiotherapy access .

Market Outlook

• According to the Bonafide research report, "Mexico Radiotherapy Market Outlook, 2031," the Mexico Radiotherapy market is anticipated to grow at more than 8.61% CAGR from 2026 to 2031. This robust growth trajectory reflects the structural deficit in radiotherapy infrastructure, rising cancer incidence, and significant government investment commitments.
• The market is expected to benefit from substantial public sector investment. The IMSS has announced the construction of 12 new radiotherapy centers in underserved states, representing a significant expansion of installed capacity. This public procurement activity will generate sustained demand for new equipment, installation services, and maintenance contracts throughout the forecast period .
• Mexico faces a substantial gap between current capacity and projected needs. The International Atomic Energy Agency projects that Mexico will require 326 megavoltage machines by 2023, a 243% increase over existing brachytherapy capacity . With cancer incidence projected to rise over 50% in the coming decades, the imperative for infrastructure expansion will only intensify .
• Technology adoption is accelerating as public institutions incorporate modern techniques including IMRT, VMAT, and SBRT. The IMSS is implementing hypofractionation protocols to optimize existing equipment utilization, while academic institutions are exploring AI-assisted planning and teledosimetry to address geographic disparities .
• Long-term growth is supported by demographic trends. Mexico's aging population adults over 60 have doubled in the past decade and will represent 28% of the population by 2050 will drive sustained cancer incidence increases. Additionally, radiotherapy's cost-effectiveness (approximately US$1,000 per complete treatment) makes it a strategic priority for public health investment .

Market Dynamics

Driver: Cancer Burden and Public Health Priority
The primary driver of the Mexican radiotherapy market is the substantial and growing cancer burden. The International Agency for Research on Cancer reported 207,154 new cancer cases and 96,210 deaths in Mexico in 2022, with cancer ranking as the third leading cause of mortality nationwide at a rate of 70.8 deaths per 100,000 inhabitants . Approximately 50% of cancer patients require radiotherapy as part of their treatment, and radiation therapy contributes to 40% of cancer cures . The recognition of radiotherapy as a cost-effective intervention a complete course of treatment costing approximately US$1,000, substantially less than other oncological therapies has elevated it as a strategic priority for the public health system. Government commitments to expand infrastructure, exemplified by the IMSS's 12 new center construction program, are translating this priority into concrete market demand .

Challenge: Infrastructure Deficit and Workforce Shortages
The most significant challenge facing the Mexican radiotherapy market is the profound infrastructure deficit. Mexico operates approximately 155-160 megavoltage machines, compared to the more than 500 units that would be required to meet international benchmarks of one linear accelerator per 250,000 inhabitants . Equipment obsolescence compounds this shortage, with a substantial portion of the installed base aged between 15 and 30 years . Only 56 hospitals have radiotherapy areas, and 34% of states possess just a single radiotherapy center, while five states lack brachytherapy entirely . A critical bottleneck is the shortage of specialized personnel, including radiation oncologists, medical physicists, dosimetrists, and technicians, with workforce concentration in Mexico City, Nuevo León, Jalisco, and the State of Mexico mirroring infrastructure inequities .



Trend: Infrastructure Expansion and Technology Modernization
A major trend reshaping the Mexican market is the accelerated infrastructure expansion and technology modernization underway across the public health sector. The IMSS has recently renewed 20 of its 30 linear accelerators, consolidating its position as the institution with the largest equipment fleet in the country . The projected construction of 12 new radiotherapy centers in underserved states represents the most significant capacity expansion in recent history . Additionally, the introduction of hypofractionation protocols reducing the number of treatment sessions while maintaining clinical efficacy is optimizing utilization of existing equipment . Academic and professional organizations, including the Mexican Society of Radiotherapists, are advocating for the development of a national modern radiotherapy network, coordinated investment in teledosimetry and AI-assisted planning, and structured workforce development programs to address the human capital deficit .

Policies

• The Comisión Federal para la Protección contra Riesgos Sanitarios regulates radiotherapy establishments under the Ley General de Salud. Facilities utilizing ionizing radiation for medical treatment must obtain a Health License (Licencia Sanitaria) for radioterapia, with a processing time of 60 business days and a filing fee of MXN 9,476.16 .
• The Comisión Nacional de Seguridad Nuclear y Salvaguardias provides nuclear safety oversight, and a CNSNS Operating License is a prerequisite for COFEPRIS health licensing. Both licenses are mandatory for operation; neither alone is sufficient .
• Personnel operating radiotherapy equipment must obtain specific permits from COFEPRIS: the "Permiso de Responsable de la Operación y Funcionamiento" for radiotherapy (COFEPRIS-05-026-C) and the "Permiso de Asesor Especializado en Seguridad Radiológica" .
• A Sanitary Construction Permit (COFEPRIS-05-039) is required before establishing a new radiotherapy facility, followed by health licensing before clinical operation commences .
• Health Canada regulates medical device imports, with radiotherapy systems classified as Class IV devices requiring a Medical Device Establishment License for importers and distributors, and a product-specific Medical Device Licence .
• The Reglamento de la Ley General de Salud en Materia de Prestación de Servicios de Atención Médica provides the legal framework for healthcare service delivery, including radiotherapy service standards and quality requirements .
• The Mexican Academy of Medicine has identified the need for strengthened governance mechanisms, coordinated investment in infrastructure and workforce, and the development of a national modern radiotherapy network to address structural deficits .

Segment Analysis

Mexico Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment in Mexico, reflecting the prevalence of linear accelerators as the primary treatment modality. The segment is driven by the high clinical demand for EBRT across common malignancies, with the IMSS leading equipment renewal. The adoption of hypofractionation protocols is optimizing EBRT capacity utilization, enabling more patients to be treated with existing equipment .
• Internal / Brachytherapy: This segment faces significant infrastructure constraints, with five Mexican states entirely lacking brachytherapy services and 34% of states having only a single radiotherapy center . The International Atomic Energy Agency projects a 243% required increase in brachytherapy capacity to meet 2030 needs . Radioactive source logistics present unique challenges, as the 74-day half-life of Iridium-192 can be compromised by lengthy administrative processes involving coordination among hospitals, manufacturers, customs, COFEPRIS, CNSNS, and the Secretariat of Finance.
• Systemic Radiotherapy: This is the fastest-growing therapy segment, fueled by the emergence of radiopharmaceuticals for conditions including thyroid cancer. The segment is import-dependent for isotopes, with supply chain constraints related to limited global reactor capacity, stringent GMP requirements, and complex cold-chain logistics. Specialized nuclear medicine infrastructure is concentrated in major urban centers.

Mexico Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by the high capital cost of linear accelerators and the structural need for equipment renewal and expansion. Mexico is fully import-dependent for complete teletherapy machines. The United States is the dominant supplier accounting for approximately 42% of X-ray and radiotherapy equipment imports valued at US$416 million followed by Germany, China, and Malaysia .
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalization of radiation oncology. The software component includes treatment planning systems, AI-assisted contouring and dose optimization tools, and teledosimetry platforms. The services component encompasses installation, maintenance, clinical training, physics support, and regulatory compliance assistance. Independent service organizations serve a significant role, particularly for older-generation equipment no longer supported by manufacturers. The IMSS's renewal of 20 accelerators has generated substantial installation and training services demand .

Mexico Radiotherapy Market By Application
• Breast Cancer: This is the largest application segment, consistent with global patterns. Breast cancer ranks among the most frequent malignancies in Mexico, with radiotherapy playing an established role in breast-conserving therapy and post-mastectomy settings. Hypofractionation protocols are being adopted to optimize equipment utilization .
• Prostate Cancer: A major application area, with prostate cancer ranking among the most frequent cancers in Mexico. EBRT and brachytherapy are standard treatment modalities. The high prevalence of this disease drives sustained equipment demand.
• Lung Cancer: Lung cancer represents a leading cause of cancer mortality in Mexico. SBRT adoption for early-stage and oligometastatic disease is increasing, though access constraints limit utilization to specialized centers .
• Head & Neck Cancer: A critical application requiring highly conformal radiation delivery. IMRT and VMAT are the standard of care, and this segment drives adoption of advanced image-guided platforms. Access is concentrated in urban academic centers.
• Central Nervous System / Brain: This is a significant application, with stereotactic radiosurgery for brain metastases and primary CNS tumors available primarily in specialized centers. The adoption of advanced techniques is constrained by equipment availability and personnel expertise .
• Gastro-intestinal: This includes esophageal, rectal, liver, and pancreatic cancers. The role of radiotherapy is expanding in pancreatic cancer, a disease with rising incidence in Mexico .
• Other Applications: Includes gynecological cancers, which are a significant cause of mortality in Mexico. Cervical cancer remains a major concern, with brachytherapy playing a critical role, highlighting the urgency of infrastructure expansion .

Mexico Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centers: This is the largest end-user segment, operating within the public health system including IMSS, ISSSTE, and IMSS-Bienestar institutions. The IMSS operates the largest fleet of linear accelerators (30 units), with 20 recently renewed . These institutions manage the most complex equipment fleets and are the primary focus of procurement activity.
• Standalone Radiotherapy Centers: This segment is growing as private healthcare providers invest in radiation oncology capacity. Private centers offer alternatives to overburdened public facilities, though costs present a barrier for many patients. This segment is more likely to adopt flexible service and maintenance models.
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their role in advancing clinical practice and technology validation. Institutions including the Instituto Nacional de Cancerología and the Mexican Academy of Medicine are at the forefront of developing quality standards, clinical guidelines, and workforce training programs .
• Other Healthcare Facilities: This includes community hospitals and regional health centers. Infrastructure is severely limited, with only 56 hospitals possessing radiotherapy areas nationwide . The IMSS's program to construct 12 new centers in underserved states targets this segment for significant expansion .

Mexico Radiotherapy Market Economics

• Service contract pricing and maintenance costs vary by equipment type and age. The significant proportion of equipment aged 15-30 years generates substantial corrective maintenance demand, while newer equipment benefits from OEM service agreements .
• Equipment procurement in Mexico is predominantly conducted through public tenders by federal and state health authorities, with the IMSS being the largest single purchaser. Group purchasing mechanisms and centralized procurement are being explored to improve efficiency and reduce costs .
• The Mexican market is fully import-dependent for complete teletherapy machines, with domestic firms participating only as component suppliers. The USMCA provides favorable tariff treatment for U.S.-origin equipment, reinforcing the United States' dominant supplier position .
• Financial constraints represent a significant economic factor. The capital required for a single linear accelerator can exceed MXN 50 million, presenting a barrier for state health systems with limited budgets. The out-of-pocket cost for private radiotherapy treatment can reach MXN 400,000, putting it beyond reach of most patients .
• Equipment downtime directly affects patient access and clinical outcomes. With only 155-160 machines for a population exceeding 130 million, any downtime creates significant treatment backlogs. Patients face waiting lists exceeding 1,500 at the National Cancer Institute .
• The economic cost of cybersecurity maintenance is an emerging factor, requiring budget allocation for software patch management and vulnerability remediation across connected device fleets, particularly as equipment becomes increasingly networked.

Market Outlook by Infrastructure, Investment and Industry Development

• The IMSS has committed to significant infrastructure expansion, with 12 new radiotherapy centers projected for construction in underserved states including Chiapas, Chihuahua, and Michoacán, representing the largest public sector investment in radiation oncology capacity in recent history .
• The renewal of 20 linear accelerators within the IMSS fleet over the past three years demonstrates an accelerating modernization cycle, generating sustained demand for new equipment, installation services, training, and maintenance support .
• Digital transformation is enabling remote diagnostics, teledosimetry, and AI-assisted treatment planning. The Mexican Academy of Medicine has identified these technologies as opportunities to address geographic disparities and optimize limited human resources .
• Workforce development is a critical priority, with medical physicists, radiation oncologists, dosimetrists, and technicians in chronic shortage. The Mexican Society of Radiotherapists and academic institutions are expanding training programs, though the pipeline requires years to produce qualified specialists .
• Regulatory coordination between COFEPRIS, CNSNS, customs, and other agencies requires strengthening, as lengthy administrative processes have been identified as a bottleneck particularly for short-half-life isotopes used in brachytherapy .
• The Mexican Academy of Medicine has called for the development of a national modern radiotherapy network coordinated by government, universities, hospitals, patients, industry, and professional organizations, with the Mexican Society of Radiotherapists playing a role in articulating academic and clinical standards .
• The long-term outlook remains positive, as cancer incidence projections exceeding 50% growth in coming decades, aging demographics, and the demonstrated cost-effectiveness of radiotherapy position Mexico as one of the region's highest-growth radiotherapy markets through 2031



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities